

Ref. No: FOI0167
Date: 09/08/23
Subject: Real-world usage of Ruxolitinib

REQUEST

Could you please tell me how many patients your Trust has treated in the past 6 months (for any disease) with the following:

- Ruxolitinib - any strength
- Ruxolitinib 5mg tablets
- Ruxolitinib 10mg tablets

In case you are able to link Ruxolitinib usage to disease, could you also provide the number of patients treated in the last 6 months for myelofibrosis ONLY with:

- Ruxolitinib - any strength
- Ruxolitinib 5mg tablets or Ruxolitinib 10mg tablets

RESPONSE

St Helen's and Knowsley Teaching Hospitals NHS Trust – Response

Could you please tell me how many patients your Trust has treated in the past 6 months (for any disease) with the following:

Treatment	No. of Patients
Ruxolitinib - any strength	10
Ruxolitinib 5mg tablets	<5
Ruxolitinib 10mg tablets	<5

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in

our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

In case you are able to link Ruxolitinib usage to disease, could you also provide the number of patients treated in the last 6 months for myelofibrosis ONLY with: Ruxolitinib - any strength, and Ruxolitinib 5mg tablets or Ruxolitinib 10mg tablets.

Indication is not recorded, so we are unable to supply this data.

Southport and Ormskirk Hospitals NHS Trust – Response

Could you please tell me how many patients your Trust has treated in the past 6 months (for any disease) with the following:

Treatment	No. of Patients
Ruxolitinib - any strength	<5
Ruxolitinib 5mg tablets	<5
Ruxolitinib 10mg tablets	<5

Section 40: personal information

Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.

In case you are able to link Ruxolitinib usage to disease, could you also provide the number of patients treated in the last 6 months for myelofibrosis ONLY with: Ruxolitinib - any strength, and Ruxolitinib 5mg tablets or Ruxolitinib 10mg tablets.

Treatment	No. of Patients
Ruxolitinib - any strength	<5
Ruxolitinib 5mg / 10mg tablets	<5

Section 40: personal information

Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.